RxDoctor Payments DataLook up a doctor →

Steven Leichter, MD

Endocrinology, Diabetes & Metabolism · Columbus, GANPI 1548302201

Payments from drug & device makers

$3,062,899in general payments, 2019–2025

Across 2,957 payments — averaging $1035.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.4M
  • Novo Nordisk AS$478K
  • Sanofi US Services Inc.$272K
  • Boehringer Ingelheim$232K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$154K
  • Acella Pharmaceuticals, LLC$102K
  • plus $455K from 54 others
$31,447in research payments, 2019–2025

Across 6 payments — averaging $5241.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$30K
  • Sanofi-aventis U.S. LLC$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)281$1,368,872
Novo Nordisk AS1,413$478,423
Sanofi US Services Inc.58$271,608
Boehringer Ingelheim52$232,415
Boehringer Ingelheim Pharma GmbH & Co.kg31$154,126
Acella Pharmaceuticals, LLC42$102,140
Takeda Pharmaceuticals U.S.A., Inc.137$89,813
Kowa Research Institute, Inc.21$68,450
Eli Lilly5$52,442
Janssen Research & Development, LLC21$50,982
Biomarin Pharmaceutical Inc.19$49,994
AstraZeneca(2 entities)3$39,918
Biogen1$23,366
Sanofi-aventis U.S. LLC69$23,365
Ionis Pharmaceuticals, Inc.17$12,473
Tandem Diabetes Care, Inc.48$11,067
Boehringer Ingelheim France S.a.s.23$8,930
Shionogi Inc3$6,056
Dexcom, Inc.25$3,154
Novo Nordisk207$2,387
Lilly USA, LLC73$1,631
Bayer37$1,359
Amgen(2 entities)51$1,247
Radius Health, Inc.41$1,214
Abbott72$1,114
Boehringer Ingelheim International GmbH10$814
Insulet Corporation29$767
BETA Bionics, Inc.9$700
Corcept Therapeutics16$528
Xeris Pharmaceuticals, Inc.24$480
Esperion Therapeutics, Inc.7$233
Rhythm Pharmaceuticals, Inc.5$221
Bigfoot Biomedical Inc2$217
Medtronic(2 entities)6$198
Ascendis Pharma Endocrinology Inc9$183
Novartis8$174
Amarin Pharma, Inc.9$173
Azurity Pharmaceuticals, Inc.8$168
Johnson & Johnson5$148
Merck8$138
Companion Medical, Inc.1$125
Amneal Pharmaceuticals LLC6$111
Lexicon Pharmaceuticals, Inc.1$105
Arbor Pharmaceuticals, Inc.6$103
Recordati_rare_diseases_inc.5$99
Kyowa Kirin, Inc.4$79
Ascensia Diabetes Care US Inc.3$54
Pfizer3$53
Chiesi USA, Inc.2$49
Intuity Medical Inc1$48
Cequr Corporation2$47
Sequel Med Tech, LLC2$38
IBSA Pharma Inc.2$35
Ferring Pharmaceuticals Inc.2$34
Madrigal Pharmaceuticals1$27
Halozyme Inc1$25
Ultragenyx Pharmaceutical Inc.1$25
Mannkind Corporation1$25
Tolmar, Inc.1$22
Amryt Pharma Holdings Ltd1$18

How this compares

$3,062,899 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024
$157,373
Medicare patients
437
Services billed
53,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Columbus

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →